By Fisentzos Stylianou, PhD Contact: [email protected] One of the main healthcare challenges raised by the European Medicines Agency’s (EMA) network strategy to 2025 is the
By Chloe Sheppard, Associate Consultant Contact: [email protected] A major milestone in the creation of pan-European joint health technology assessment (HTA) was reached in January this
By Andrea Bernardini, Senior Analyst Email: [email protected] AIFA has approved reimbursement of the orphan drug Evrysdi (risdiplam) by Roche, the first at-home oral treatment for Spinal
By Andrea Bernardini, Senior Analyst Email: [email protected] Intensifying pressure to implement cost savings due to COVID induced economic downturn and the current ruling coalition, seem
By Andrea Bernardini, Senior Analyst Email: [email protected] The latest approved Budget Law for the three-year period 2022-2024 is quite extensive and covers the whole planned spending
By Jens Leutloff, Senior Consultant Email [email protected] The discussion of cost containment measures in the German healthcare system does not seem to stop, and could
By Andrea Bernardini, Analyst & Akshay Kumar, Partner Email: [email protected] [email protected] On the 12th of February the Orphan Drugs Observatory and the Italian Society of
By Akshay Kumar, Partner & Andrea Bernardini, Analyst Email: [email protected] [email protected] In the latest guidelines for Pricing and Reimbursement (P&R) dossier submissions, Italian Medicines Agency
By Erfan Akbraian, Analyst Email: [email protected] In recent years there have been discussions to shift to a multi-stakeholder approach and increase early communication amongst key
